Phase Transfer Catalyzed Synthesis of Cetirizine Intermediate

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

The existing processes for preparing {2-[4-(α-phenyl-p-chlorobenzyl)-piperazin-1-yl]-ethoxy}-acetic acid-N,N-dimethylamide are inefficient due to side reactions, costly purification requirements, and the need for moisture-free conditions, leading to yield loss and complexity.

Innovation Solution

Reacting 1-(α-phenyl-p-chlorobenzyl)-piperazine with (2-chloroethoxy)-acetic acid-N,N-dimethylamide in an indifferent solvent with an acid-binding agent and catalyst, avoiding moisture-free operations and minimizing side product formation, allowing direct conversion to cetirizine or levocetirizine.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Manufacturing precision

If 2-chloroethoxy-acetamide is reacted with 1-(α-phenyl-p-chlorobenzyl)-piperazine in xylene solvent with anhydrous sodium carbonate, then cetirizine intermediate is formed, but alkylation of the amino group occurs as side reaction requiring costly purification

Engineering Contradiction:

Improveproduct purityVSAvoidpurification complexity

Core Design Contradiction:

Manufacturing precisionVSEase of manufacture

Solution Approach 1:

The patent introduces a phase transfer catalyst (such as tetraalkylammonium halides) as an intermediary substance that mediates the reaction between the aqueous phase containing 2-chloroethoxy-acetamide and the organic phase containing 1-(α-phenyl-p-chlorobenzyl)-piperazine. This catalyst facilitates the desired O-alkylation reaction while preventing side reactions, thereby improving product purity and eliminating the need for costly purification processes.

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent changes the reaction parameters by using a two-phase system (aqueous-organic) instead of a single organic solvent system, and by controlling the pH through buffer solutions. These parameter changes optimize the reaction conditions to favor the desired product formation while suppressing side reactions, thus improving manufacturing precision without increasing purification complexity.

Inventive Principle:

Principle #35Parameter changes

2Manufacturing precision

If O-alkylation is carried out in moisture-free solution, then side product formation is reduced, but special equipment and moisture-free reagents are required

Engineering Contradiction:

Improveside product formationVSAvoidequipment requirements

Core Design Contradiction:

Manufacturing precisionVSDevice complexity

Solution Approach 1:

The patent creates an inert environment by using a two-phase reaction system where the organic phase acts as a protective layer, and the phase transfer catalyst operates at the interface. This approach provides the benefits of moisture-free conditions for reducing side products without requiring expensive special equipment or moisture-free reagents, as the system naturally excludes water from the reaction zone.

Inventive Principle:

Principle #39Inert atmosphere (Inert environment)

3Manufacturing precision

If conventional purification processes are used to remove side products, then product purity is improved, but yield loss increases significantly

Engineering Contradiction:

Improveproduct purityVSAvoidyield loss

Core Design Contradiction:

Manufacturing precisionVSLoss of substance

Solution Approach 1:

The patent converts the potential harm of side reactions into a benefit by using the phase transfer catalysis mechanism to selectively promote the desired O-alkylation reaction. The phase transfer catalyst specifically facilitates the formation of the desired product while suppressing amino group alkylation side reactions, thereby achieving high product purity without significant yield loss through simple phase separation instead of costly purification.

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

This process reduces side product formation, eliminates the need for costly moisture-free conditions, and ensures the production of optically pure levocetirizine without racemization, achieving high purity and yield suitable for pharmacopoeial quality cetirizine production.

Implementation Method 1

reacting 1-(α-phenyl-p-chlorobenzyl)-piperazine of the Formula (II) and (2-chloroethoxy)-acetic acid-N,N-dimethylamide of the Formula (III) in an indifferent solvent and in the presence of an acid-binding agent and a catalyst

Methodology Applied

Scientific EffectAcid-base neutralization: Chemical Bonding

Implementation Method 2

Methodology Applied

Scientific EffectCatalysis: Catalysis

Data Source

PatentEP1971585B1Process for the preparation of a pharmaceutical intermediate

Publication Date: 2011.03.09 EGIS GYOGYSZERGYAR NYILVANOSAN MUKODO RESZVENY TARSASAG

AI summary

The present invention relates to a process for the preparation of {2-[4-(a-phenyl-p-chlorobenzyl)-piperazin-1-yl]-ethoxy}-acetic acid-N,N-dimethylamide of the Formula (I) and enantiomers thereof. The compound of the Formula (I) or enantiomers thereof are important pharmaceutical intermediates suitable for direct transformation into non-sedating antihistamine type pharmaceutical active ingredients cetirizine and levocetirizine.